• EVOTEC RECEIVES ACCESS TO AN INTERNATIONAL COHORT OF NEPHROTIC SYNDROME PATIENTS COORDINATED BY THE UNIVERSITY OF BRISTOL
• THE COHORT PROVIDES LONGITUDINAL ACCESS NOT ONLY TO CLINICAL DATA BUT IN PARTICULAR ALSO TO BIOSPECIMENS
• EVOTEC WILL LEVERAGE ITS MULTI-OMICS ANALYSIS PLATFORM EVOPANOMICS AND THE DATA ANALYTICS PLATFORM EVOPANHUNTER TO IDENTIFY KEY MECHANISMS OF DISEASE AND DIAGNOSTIC MARKERS

Hamburg, Germany, 01 March 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a collaboration with the University of Bristol ("UoB") to expand the Company's molecular patient database in the field of kidney diseases with a focus on nephrotic syndrome. The nephrotic syndrome is a group of symptoms like proteinuria and oedema that indicate kidneys are not working properly. Diagnosis remains challenging and current treatment regimens are mostly symptomatic.

Under the collaboration, Evotec receives access to longitudinal samples from an international cohort which includes several hundreds of patients from Asia, India and Africa linked to anonymised clinical records. Evotec will analyse the samples using its proprietary multi-omics platform EVOpanOmics. Expert teams at Evotec and the UoB will leverage Evotec's data analytics and prediction platform EVOpanHunter to jointly identify key drivers of nephrotic syndrome disease progression, potential molecular targets for intervention as well as molecular markers for diagnosis.

Molecular patient data combined with clinical data is instrumental for the identification and validation of disease-relevant molecular mechanisms and targets. Stratification of patients according to disease-associated molecular mechanisms re-classify certain subtypes of the disease, i.e. steroid sensitive and steroid resistant nephrotic syndrome ("SSNS", and "SRNS", respectively) and deliver new starting points for the discovery of novel targeted therapies.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very pleased to further expand our molecular patient database in the field of kidney diseases through this collaboration with the University of Bristol. This unusual longitudinal study of nephrotic syndrome patients provides a unique basis to identify molecular markers for proper diagnosis as well novel molecular targets to develop disease-modifying therapeutics."

Prof. Moin Saleem, Director Bristol Renal and Professor of Paediatric Renal Medicine at the University of Bristol, added: "This is a unique collaborative opportunity with Evotec to interrogate valuable clinical samples from an international cohort using cutting edge technology. Ultimately it will benefit patients with nephrotic syndrome, where specific targeted therapies are desperately needed."


ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com